Delhi High Court sought Explanation through Counter Affidavit over Repudiation of Patent application for Xtandi
Xtandi, the wonder drug for prostate cancer, was developed at UCLA, Los Angeles, by the innovation of NIH and Department of Defense grants. The drug was later licensed to Medivation, a biopharma company, which in October 2009 struck a deal…